Monroe Capital (MRCC) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
6 Mar, 2026Executive summary
Supplement amends and updates the joint proxy statement/prospectus for a proposed transaction between two entities, referencing recent annual and current reports for both parties.
Voting matters and shareholder proposals
Shareholders are being asked to review and vote on matters related to the joint proxy statement/prospectus, as updated by this supplement.
Board of directors and corporate governance
The supplement is issued jointly by both entities, indicating coordinated governance and oversight for the proposed transaction.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Monroe Capital
- Both asset sale and merger proposals were approved by a majority of outstanding shares.MRCC
EGM 202613 Mar 2026 - Supplemental distributions and enhanced merger terms were approved to address shareholder concerns.MRCCProxy Filing11 Mar 2026
- Net investment income and NAV declined year-over-year, with merger expected to unlock value.MRCCQ4 20255 Mar 2026
- Director election and share sale authorization approved; no shareholder questions raised.MRCCAGM 20243 Feb 2026
- Adjusted NII rose to $0.31/share, covering the dividend as NAV and leverage declined.MRCCQ2 20242 Feb 2026
- Shareholders to vote on merger and asset sale, with NAV-based share exchange and fee waiver.MRCCProxy Filing20 Jan 2026
- Dividend coverage strong, NAV dipped, non-accruals up, Wendel partnership adds $1B capital.MRCCQ3 202414 Jan 2026
- Q4 income covered dividends; NAV dipped, but 2025 outlook targets growth and risk discipline.MRCCQ4 202416 Dec 2025
- Shareholders to vote on unchanged advisory agreement after Wendel acquires 75% of Monroe.MRCCProxy Filing2 Dec 2025